GSK plc today announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with intranasal corticosteroids

Atavistik Bio, a biotechnology company committed to discovering the next generation of precision allosteric therapeutics inspired by the body’s natural regulators, today announced that it has entered into a research collaboration with Pfizer

ANI Pharmaceuticals, Inc. today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company has launched Prucalopride Tablets. ANI’s Prucalopride Tablets is the generic version of the reference listed drug (RLD) Motegrity®.

SciSparc Ltd a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the renewal of its approval

Duality Biologics announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate

YolTech Therapeutics, a clinical-stage in vivo gene editing company, announced that the U.S. Food and Drug Administration.

Argenx SE a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Japan’s Ministry of Health, Labour and Welfare

Axcelead Drug Discovery Partners, Inc. announced today that it has entered into a drug discovery service agreement with Astellas Pharma, Inc

OBI Pharma, Inc. (OBI), a global clinical-stage oncology company focused on developing novel cancer therapies such as antibody-drug conjugates (ADCs) and active immunotherapies (4174. TWO), and GlyT

Bristol Myers Squibb  today announced that the European Commission (EC) has approved Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).